VIBROSENSE DYNAMICS AB CLASS B
NNGM:VSD.B0.54
SEK
+0.01
(+1.90%)
ISIN
SE0006852125
Return %
Stock
S&P 500
1Y
-61.71
14.20
3Y
-91.24
81.12
5Y
-94.08
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Cengiz Tarik
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Malmö Sweden
- IPO Date
- May 4, 2015
- Website
- vibrosense.eu
- Similar Companies
- Business
- VibroSense Dynamics AB VibroSense Dynamics AB develops, manufactures and sells medical devices and related services that support the early detection and quantitative diagnosis of peripheral sensory neuropathy, a condition affecting large nerve fibers and trunks in hands and feet; its flagship product, the VibroSense Meter II, employs multi-frequency vibrometry technology to measure vibration perception thresholds non-invasively across multiple frequencies, enabling subclinical detection with automatic comparison to age- and gender-matched reference data from over 1,100 healthy individuals, wireless skin temperature measurement, and compliance with ISO 13091-1 standards. The company offers procurement options including outright purchase, rental and service agreements covering annual maintenance, software updates, calibration every two years and remote support; complementary services encompass specialized training on instrument operation and vibrogram interpretation, research consulting for study design and data analysis, and Hand HAVS Screening for occupational health surveillance of workers exposed to hand-held vibrating tools per EU Directive 2002/44/EC. Founded in 2005 and headquartered at Medeon Science Park in Malmö, Sweden, VibroSense Dynamics AB operates primarily in the healthcare equipment sector, targeting diabetes clinics, cancer treatment centers, occupational health providers, hospitals, research institutes and primary care across the Nordics, Europe and emerging markets including China; the VibroSense Meter system sees widespread adoption at major university hospitals in Sweden and Norway for diagnosing diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN) and hand-arm vibration syndrome (HAVS). Recent developments include receipt of China National Medical Products Administration (NMPA) approval for VibroSense Meter II in May 2025 to facilitate market entry via partner UMCare, despite subsequent delivery delays to spring 2026 amid organizational adjustments and new public procurement restrictions; leadership changes feature co-founder Toni Speidel assuming CEO role on September 1, 2025, following Tarik Cengiz's appointment as CEO in September 2024, alongside additions to the marketing, sales team and a dedicated China Key Account Manager. The company pursues geographic expansion through international congress participation, distributor partnerships in Germany and evaluations of two to three additional markets post-2024 share issue proceeds, while advancing research collaborations such as with Complutense University of Madrid's Diabetic Foot Unit and securing new patents.